---
format: "aidr-story-markdown/v1"
id: "9fed456d750d70061cde82018200edbf645a850a1ba155ad61c167124cbeaab2"
canonical_url: "https://aidr.today/9fed456d?lang=en"
title: "Isomorphic Labs Raises $5B in Series C to Accelerate AI Drug Discovery"
lang: "en"
requested_lang: "en"
available_langs: ["en","vi"]
translation_fallback: null
fallback_fields: []
published_at: "2026-11-17T12:21:36.000Z"
category: "Funding"
topics: ["google","funding"]
source_urls: ["https://marketbrief.now/startups/isomorphic-labs-raises-5b-in-series-c-to-accelerate-ai-drug-discovery-fee573c0","https://x.com/IsomorphicLabs/status/2122661054723547449","https://x.com/demishassabis/status/2122662616367853670","https://x.com/wallstengine/status/2122663092597453174","https://x.com/business/status/2122659810550091982","https://huggingnews.com/startups/isomorphic-labs-raises-5b-in-series-c-to-accelerate-ai-drug-discovery-fee573c0"]
summary: "Alphabet's AI drug-discovery company Isomorphic Labs raised $5 billion in a Series C round co-led by Sequoia Capital and Greenoaks. New investor Andreessen Horowitz joined the round, which also included existing backers Thrive Capital, GV and CapitalG. CEO Demis Hassabis said the capital will accelerate the company's progress toward human clinical trials, supporting more than 20 drug-development programs for cancer, inflammation and immune disorders. The investment follows a $2.1 billion raise in May, totaling $7.1 billion in funding over the last six months. While Isomorphic works with partners including Eli Lilly, Novartis and Johnson & Johnson, no AI-designed drug has yet received regulatory approval and the company has not provided a specific timeline for its first clinical trials."
---

# Isomorphic Labs Raises $5B in Series C to Accelerate AI Drug Discovery

> [Open the canonical story](<https://aidr.today/9fed456d?lang=en>)

**Published:** 2026-11-17T12:21:36.000Z
**Category:** Funding
**Topics:** google, funding

## Summary

Alphabet's AI drug\-discovery company Isomorphic Labs raised $5 billion in a Series C round co\-led by Sequoia Capital and Greenoaks\. New investor Andreessen Horowitz joined the round, which also included existing backers Thrive Capital, GV and CapitalG\. CEO Demis Hassabis said the capital will accelerate the company's progress toward human clinical trials, supporting more than 20 drug\-development programs for cancer, inflammation and immune disorders\. The investment follows a $2\.1 billion raise in May, totaling $7\.1 billion in funding over the last six months\. While Isomorphic works with partners including Eli Lilly, Novartis and Johnson &amp; Johnson, no AI\-designed drug has yet received regulatory approval and the company has not provided a specific timeline for its first clinical trials\.

## Sources

- [Story source](<https://marketbrief.now/startups/isomorphic-labs-raises-5b-in-series-c-to-accelerate-ai-drug-discovery-fee573c0>)
- [Story source](<https://x.com/IsomorphicLabs/status/2122661054723547449>)
- [Story source](<https://x.com/demishassabis/status/2122662616367853670>)
- [Supporting source](<https://x.com/wallstengine/status/2122663092597453174>)
- [Story source](<https://x.com/business/status/2122659810550091982>)
- [Story source](<https://huggingnews.com/startups/isomorphic-labs-raises-5b-in-series-c-to-accelerate-ai-drug-discovery-fee573c0>)

